CN103585189B - The application of wall tapestry extract in preparation antiviral drugs - Google Patents
The application of wall tapestry extract in preparation antiviral drugs Download PDFInfo
- Publication number
- CN103585189B CN103585189B CN201310525392.9A CN201310525392A CN103585189B CN 103585189 B CN103585189 B CN 103585189B CN 201310525392 A CN201310525392 A CN 201310525392A CN 103585189 B CN103585189 B CN 103585189B
- Authority
- CN
- China
- Prior art keywords
- wall tapestry
- extract
- tapestry extract
- wall
- obtains
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000284 extract Substances 0.000 title claims abstract description 139
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 239000003443 antiviral agent Substances 0.000 title claims abstract description 17
- 239000000341 volatile oil Substances 0.000 claims abstract description 19
- 239000011347 resin Substances 0.000 claims abstract description 13
- 229920005989 resin Polymers 0.000 claims abstract description 13
- 239000003463 adsorbent Substances 0.000 claims abstract description 8
- 238000000605 extraction Methods 0.000 claims description 55
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 52
- 239000003814 drug Substances 0.000 claims description 42
- 229940079593 drug Drugs 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 239000002904 solvent Substances 0.000 claims description 18
- 238000010438 heat treatment Methods 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 239000006286 aqueous extract Substances 0.000 claims description 9
- 238000010992 reflux Methods 0.000 claims description 9
- 238000001256 steam distillation Methods 0.000 claims description 9
- 230000001476 alcoholic effect Effects 0.000 claims description 8
- 239000012141 concentrate Substances 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 8
- 239000003480 eluent Substances 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 6
- 230000000274 adsorptive effect Effects 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 abstract 1
- 238000002481 ethanol extraction Methods 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 28
- 241000700605 Viruses Species 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 20
- 230000000844 anti-bacterial effect Effects 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 239000001963 growth medium Substances 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 210000003501 vero cell Anatomy 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical group N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 7
- 229960004150 aciclovir Drugs 0.000 description 7
- 230000000903 blocking effect Effects 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 241000222122 Candida albicans Species 0.000 description 6
- 230000000840 anti-viral effect Effects 0.000 description 6
- 230000009849 deactivation Effects 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 5
- 229940095731 candida albicans Drugs 0.000 description 5
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 5
- 229960003376 levofloxacin Drugs 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 206010059866 Drug resistance Diseases 0.000 description 4
- 238000012449 Kunming mouse Methods 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000002155 anti-virotic effect Effects 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 4
- 230000001408 fungistatic effect Effects 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- QGZCUOLOTMJILH-UHFFFAOYSA-N 2h-tetrazol-2-ium;bromide Chemical compound [Br-].C1=N[NH+]=NN1 QGZCUOLOTMJILH-UHFFFAOYSA-N 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 208000035357 Focal Infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 231100000645 Reed–Muench method Toxicity 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- -1 and dry Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000007510 mood change Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a kind of novelty teabag of wall tapestry extract, this novelty teabag is the application of wall tapestry extract in preparation antiviral drugs.Described wall tapestry extract is prepared as follows: take wall tapestry as raw material, first extract volatile oil, then uses 30%-75% ethanol extraction, is obtained by macroporous adsorbent resin, neutral alumina purification.Wall tapestry extract provided by the present invention is significant to preparation antiviral drugs.
Description
Technical field
The invention belongs to biomedicine field, relate to the application of a kind of Chinese medicinal material extract in preparation antiviral drugs, specifically relate to the application of wall tapestry extract in preparation antiviral drugs.
Background technology
At present a large amount of bacterial drug resistance using antibiotic to cause constantly rises has become one of difficult problem of jointly paying close attention in the whole world.Especially the resistant rate of staphylococcus aureus reaches more than 90%.Herpes simplex virus type II mainly causes genital area mucocutaneous infections.Virus enters body through respiratory tract, oral cavity, genital mucosa and damaged skin, dives and occupy in human normal mucosa, blood, saliva and sensory nerve ganglion cell.When Abwehrkraft des Koepers declines, as heating, gastrointestinal dysfunction, menstruation, gestation, focal infection and mood change time, the HSV-II hidden in body is activated and falls ill.The antiviral drugs that synthetic drug is comparatively affirmed in the treatment of herpes simplex is acyclovir (ACV), but the persister of clinical continuous discovery ACV in recent years, and drug resistance has growth trend with the prolongation of courses of pharmaceuticals.
Therefore, antibacterial, the antiviral drugs of developing new high-efficiency low-toxicity have broad prospects, the multiple target effect mechanism of Chinese medicine, low toxic and side effects, be easy to metabolism, the advantage such as to have no drug resistance makes it become the focus of antibacterial, the antiviral drugs of screening high-efficiency low-toxicity.
Wall tapestry is the dry thallus of lichens Teloshistaceae plant wall tapestry Theloschestes flavicans (Sw.) Norm.After collection, removing earth, dries.Record in " Drug Standard of Ministry of Public Health of the Peoples Republic of China Tibetan medicine (first) ", standard number: WS3-BC-0125-95.Cool in nature, bitter in the mouth.There is heat extraction, effect of removing toxic substances.For lung-heat, liver-heat, arteries and veins heat, scorchingly hot.The common drug of the minority areas such as illiteracy is hidden for China.But about the basic research of wall tapestry is still very limited, the follow-up promotion and application of this medical material are restricted.Relevant wall tapestry chemical composition and pharmacological research have no report.Domestic patent search result, has no wall tapestry Patents.
Above-mentioned document and patent etc., there is not yet wall tapestry or wall tapestry extract is antibacterial, the report of antivirus action research.
Summary of the invention
The object of the present invention is to provide the application of wall tapestry extract in preparation antiviral drugs.
The present invention is achieved through the following technical solutions:
The present invention's wall tapestry used is the dry thallus of lichens Teloshistaceae plant wall tapestry Theloschestes flavicans (Sw.) Norm.
The application of wall tapestry extract of the present invention in preparation antiviral drugs, the preparation method that described wall tapestry extract is is:
(1) wall tapestry, adds 8-15 times of water gaging, soaks 4-12 hour, adopts extraction by steam distillation volatile oil, extraction time 1-4 hour, extraction time 1-3 time, collects volatile oil, obtains wall tapestry extract A; Wall tapestry aqueous extract is filtered, obtains extracting solution A and medicinal residues A respectively;
(2) step (1) being obtained medicinal residues A concentration 50%-95% ethanol is solvent, heating and refluxing extraction, and extraction time is 1-3 time, and each extraction time is 1-3 hour, each solvent load is 8-15 times of wall tapestry weight, filters, and extracting solution reclaims ethanol, concentrated, dry, obtain wall tapestry extract B;
(3) by the extracting solution A that step (1) obtains, be concentrated into relative density d=1.10-1.20, pass through macroporous adsorptive resins, first wash with water, then use the alcoholic solution eluting of concentration 50%-70%, collect different concentration ethanol eluent, concentrate drying, obtains wall tapestry extract C;
(4) by above-mentioned wall tapestry extract A, wall tapestry extract B, wall tapestry extract C, wherein one or both or three kinds mix by a certain percentage, obtain wall tapestry extract of the present invention.
The preparation method of wall tapestry extract is:
(1) wall tapestry, adds 8-15 times of water gaging, soaks 4-12 hour, adopts extraction by steam distillation volatile oil, extraction time 1-4 hour, extraction time 1-3 time, collects volatile oil, obtains wall tapestry extract A; Wall tapestry aqueous extract is filtered, obtains extracting solution A and medicinal residues A respectively;
(2) step (1) being obtained medicinal residues A concentration 50%-95% ethanol is solvent, heating and refluxing extraction, and extraction time is 1-3 time, and each extraction time is 1-3 hour, each solvent load is 8-15 times of wall tapestry weight, filters, and extracting solution reclaims ethanol, concentrated, dry, obtain wall tapestry extract B;
(3) by the extracting solution A that step (1) obtains, be concentrated into relative density d=1.10-1.20, pass through macroporous adsorptive resins, first wash with water, then use the alcoholic solution eluting of concentration 50%-70%, collect different concentration ethanol eluent, concentrate drying, obtains wall tapestry extract C;
(4) by above-mentioned wall tapestry extract A, wall tapestry extract B, the mixing of wall tapestry extract C, wall tapestry extract of the present invention is obtained.
The preparation method of preferred wall tapestry extract is:
(1) wall tapestry, adds 12 times of water gagings, soaks 6 hours, adopts extraction by steam distillation volatile oil, 2 hours extraction times, extraction time 2 times, collects volatile oil, obtains wall tapestry extract A; Wall tapestry aqueous extract is filtered, obtains extracting solution A and medicinal residues A respectively;
(2) step (1) being obtained medicinal residues A concentration 70% ethanol is solvent, heating and refluxing extraction, and extraction time is 2 times, and each extraction time is 2 hours, each solvent load is 12 times of wall tapestry weight, filters, and extracting solution reclaims ethanol, concentrated, dry, obtain wall tapestry extract B;
(3) by the extracting solution A that step (1) obtains, be concentrated into relative density d=1.12, by DM130 macroporous adsorbent resin, first wash with water, then use the alcoholic solution eluting of concentration 60%, collect 60% concentration ethanol eluent, concentrate drying, obtain wall tapestry extract C;
(4) by above-mentioned wall tapestry extract A, wall tapestry extract B, the mixing of wall tapestry extract C, wall tapestry extract of the present invention is obtained.
The preparation method of wall tapestry extract of the present invention, is characterized in that: the macroporous adsorbent resin adopted is D101 macroporous adsorbent resin, DM130 macroporous adsorbent resin, ADS-17 macroporous adsorbent resin.
Wall tapestry extract A of the present invention, wall tapestry extract B, wall tapestry extract C, the application in preparation antiviral drugs.
The antiviral drugs that wall tapestry extract of the present invention and chemical drugs or Chinese medicine or natural drug form.
Wall tapestry extract A of the present invention, wall tapestry extract B, wall tapestry extract C, the antiviral drugs formed with chemical drugs or Chinese medicine or natural drug.
Wall tapestry extract of the present invention, by adding the various adjuvants that pharmaceutics allows, makes the peroral dosage forms such as the tablet on pharmaceutics, granule, capsule.
Wall tapestry extract of the present invention is by multicomponent, and too many levels, multipath ground plays synergism and shows antiviral efficacy, invades to HSV-II the Main Function approach that the blocking effect of cell and direct kill virus are wall tapestry extracorporeal antivirus effects.HSV-II is tunicary virus, and outermost peplos is made up of lipid and glycoprotein, and wherein any one composition changes, and can make peplos degeneration, thus inactivation of viruses.Experimental result shows that each extract of wall tapestry is comparatively strong to the direct deactivation of HSV-II, and especially the effect of wall tapestry extract and wall tapestry extract A direct deactivation HSV-II is more remarkable than ACV.Therefore infer that these chemical compositions can make peplos degeneration with inactivation of viruses.The blocking effect research that HSV-II invades cell shows, wall tapestry extract not only has antiviral activity, also has the effect that to a certain degree Cell protection prevents Virus entry.Utilize HSV-II encephalitis model to study wall tapestry extract to the protective effect of HSV-II infecting mouse, result shows that wall tapestry extract shows certain antiviral activity.
Detailed description of the invention
Below by specific experiment example and embodiment, the application of wall tapestry extract in preparation antiviral drugs is described further, but is not limited to the present invention.
Embodiment 1: the preparation of wall tapestry extract
(1) wall tapestry, adds 12 times of water gagings, soaks 6 hours, adopts extraction by steam distillation volatile oil, 2 hours extraction times, extraction time 2 times, collects volatile oil, obtains wall tapestry extract A; Wall tapestry aqueous extract is filtered, obtains extracting solution A and medicinal residues A respectively;
(2) step (1) being obtained medicinal residues A concentration 70% ethanol is solvent, heating and refluxing extraction, and extraction time is 2 times, and each extraction time is 2 hours, each solvent load is 12 times of wall tapestry weight, filters, and extracting solution reclaims ethanol, concentrated, dry, obtain wall tapestry extract B;
(3) by the extracting solution A that step (1) obtains, be concentrated into relative density d=1.12, by DM130 macroporous adsorbent resin, first wash with water, then use the alcoholic solution eluting of concentration 60%, collect 60% concentration ethanol eluent, concentrate drying, obtain wall tapestry extract C;
(4) above-mentioned wall tapestry extract A, wall tapestry extract B and wall tapestry extract C are mixed, obtain wall tapestry extract of the present invention.
Embodiment 2: the preparation of wall tapestry extract
(1) wall tapestry, adds 8 times of water gagings, soaks 12 hours, adopts extraction by steam distillation volatile oil, 1 hour extraction time, extraction time 3 times, collects volatile oil, obtains wall tapestry extract A; Wall tapestry aqueous extract is filtered, obtains extracting solution A and medicinal residues A respectively;
(2) step (1) being obtained medicinal residues A concentration 50% ethanol is solvent, heating and refluxing extraction, and extraction time is 1 time, and each extraction time is 3 hours, each solvent load is 15 times of wall tapestry weight, filters, and extracting solution reclaims ethanol, concentrated, dry, obtain wall tapestry extract B;
(3) by the extracting solution A that step (1) obtains, relative density d=1.20 is concentrated into, by HPD600 macroporous adsorptive resins, first wash with water, then use the alcoholic solution eluting of concentration 50%, collect 50% concentration ethanol eluent, concentrate drying, obtains wall tapestry extract C;
(4) above-mentioned wall tapestry extract A, wall tapestry extract B and wall tapestry extract C are mixed, obtain wall tapestry extract of the present invention.
Embodiment 3: the preparation of wall tapestry extract
(1) wall tapestry, first adds 15 times of water gagings, soaks 4 hours, adopts extraction by steam distillation volatile oil, 4 hours extraction times, extraction time 1 time, collects volatile oil, obtains wall tapestry extract A; Wall tapestry aqueous extract is filtered, obtains extracting solution A and medicinal residues A respectively;
(2) step (1) being obtained medicinal residues A concentration 95% ethanol is solvent, heating and refluxing extraction, and extraction time is 3 times, and each extraction time is 1 hour, each solvent load is 8 times of wall tapestry weight, filters, and extracting solution reclaims ethanol, concentrated, dry, obtain wall tapestry extract B;
(3) by the extracting solution A that step (1) obtains, be concentrated into relative density d=1.10, by D101 macroporous adsorptive resins, first wash with water, then use the alcoholic solution eluting of concentration 70%, collect 70% concentration ethanol eluent, concentrate drying, obtain wall tapestry extract C;
(4) above-mentioned wall tapestry extract A, wall tapestry extract B and wall tapestry extract C are mixed, obtain wall tapestry extract of the present invention.
Embodiment 4: the preparation of wall tapestry extract
(1) wall tapestry, first adds 10 times of water gagings, soaks 6 hours, adopts extraction by steam distillation volatile oil, 3 hours extraction times, extraction time 2 times, collects volatile oil, obtains wall tapestry extract A; Wall tapestry aqueous extract is filtered, obtains extracting solution A and medicinal residues A respectively;
(2) step (1) being obtained medicinal residues A concentration 70% ethanol is solvent, heating and refluxing extraction, and extraction time is 2 times, and each extraction time is 2 hours, each solvent load is 12 times of wall tapestry weight, filters, and extracting solution reclaims ethanol, concentrated, dry, obtain wall tapestry extract B;
(3) by above-mentioned wall tapestry extract A, the mixing of wall tapestry extract B, wall tapestry extract of the present invention is obtained.
Embodiment 5: the preparation of wall tapestry extract sheet
Example 1 wall tapestry extract 185g, adds starch 70g, mixing, granulates, sieves, add microcrystalline Cellulose 9.5g, magnesium stearate 2.0g, and mixing, is pressed into 1000, obtains wall tapestry extract sheet.
Embodiment 6: the preparation of wall tapestry extract particles
Example 2 wall tapestry extract 175g, adds dextrin 95g, sucrose 35g, mixing, granulates, and dry, granulate, obtains wall tapestry extract particles.
Embodiment 7: the preparation of wall tapestry extract capsule
Example 3 wall tapestry extract 180g, adds starch 65g, mixing, and granulate, granulate, adds magnesium stearate 1.5g, and mixing, obtains wall tapestry extract capsule by encapsulated 1000.
Experimental example 1: wall tapestry extract antibacterial action.
1. strain and culture medium
Experimental strain is provided by Center for Disease Control (CDC) of Shandong Province and Clinical Laboratory center, Shandong Province.Be listed as follows:
Experiment culture medium: antibacterial MH culture medium, fungus PDA culture medium is all purchased from Nat'l Pharmaceutical & Biological Products Control Institute.
2. fungistatic effect detection method:
2.1 fungistatic effects cylinder plate method measures inhibition zone size
Activation bacterium liquid physiological saline solution is diluted to 10
5-10
6cfu/ml is for subsequent use.Add 0.2ml bacterium liquid to dry MH culture medium flat plate, smoothen.Place 5min, make culture medium fully absorb bacterium liquid.6, sterilized Oxford cup placed by each flat board, places 5min, makes Oxford cup adsorbed close in media surface.The each medicine 100ul of 0.1g/ml is added in the cup of Oxford.Positive control levofloxacin and fluconazol.Positive control antibacterial concentration is 40 μ g/ml levofloxacin, and Candida albicans concentration is 200 μ g/ml fluconazol, all adds 100ul.Negative control adds sterilized water.Then flat board is placed in 37 DEG C of constant incubators and cultivates 24h (candida albicans 48h), go out and measure antibacterial circle diameter with slide calliper rule, calculating mean value, represent bacteriostatic activity with antibacterial circle diameter D.Fungistatic effect criterion is: D≤8mm is insensitive, and 8mm < D≤13mm is less sensitive, and 13mm < D≤19mm is medium sensitivity, and D > 19mm is extremely sensitive.
The mensuration of 2.2 minimal inhibitory concentration MIC adopts Microdilution plate method
Test bacterial concentration is 10
6cfu/ml.Drawing the bacterium liquid diluted is added in 96 porocyte culture plates, and every hole 100ul, often kind of medicine 100ul contrast dilution 10 hole successively, and last hole does not add medicine (only adding culture medium and antibacterial) and adds dilution bacterium liquid 100ul, is bacterial growth control hole.Stay string hole not add antibacterial (only adding culture medium and medicine) and do drug control hole, positive control levofloxacin and fluconazol, illustratively do doubling dilution.Be placed in 1min that agitator vibrates, make after in hole, solution fully mixes, microwell plate is added a cover and is placed on and is covered with in the square enamel tray of wet gauze, in 37 DEG C of incubators, hatch 24h (candida albicans 48h), observe and be minimal inhibitory concentration without lowest concentration of drug contained by bacterial growth hole.
3. fungistatic effect
Table 1 different wall tapestry extract inhibition zone (mm)
Note: a, wall tapestry extract, wall tapestry extract C, wall tapestry extract A, wall tapestry extract B addition are 1mg/ cup, b, positive control antibacterial concentration are 40 μ g/ml levofloxacin, Candida albicans concentration is 200 μ g/ml fluconazol, all adds 100ul.5%DMSO is negative control.
Table 2 different wall tapestry extract minimal inhibitory concentration (MIC) (unit mg/ml)
Note: positive control antibacterial levofloxacin, Candida albicans fluconazol, all adds 100ul.5% DMSO is negative control.
Result shows: wall tapestry extract has broad-spectrum antiseptic and bactericidal action.To gram positive bacteria: staphylococcus aureus, drug resistance staphylococcus epidermidis, bacillus cereus, bacillus subtilis; Gram negative bacteria: escherichia coli, enterococcus faecalis; Deep infection fungus Candida albicans has the effect killed with Developing restraint, has important practice significance and using value, can have in the food of antibacterial and/or bactericidal action, health product, cosmetics and medicine apply in preparation.
Experimental example 2: wall tapestry extract antivirus action.
1. experiment material
Virus: HSV-II type (3 generation) 20110913, Lanzhou Institute of Biological Products's vaccine research room provides (herpessimplex virus, HSV-II).
Cell: African green monkey kidney cell (Vero cell) Lanzhou Institute of Biological Products provides.Cultivate with DMEM culture medium+7% Ox blood serum.
Animal: cleaning grade kunming mice, male and female half and half, body weight 18-22g, is purchased from Lanzhou Institute of Biological Products's Animal House.
Medicine and reagent: tetrazolium bromide (MTT, Fluka Biochemika company), dimethyl sulfoxide (dimethylsulfoxide, DMSO, Sigma company produces), DMEM (GIBCO company), standard neonatal Ox blood serum (sino-america joint-venture Lanzhou people's marine growth Engineering Co., Ltd), Aciclovir for injection (ACV, 9-(2-hydroxyl ethoxymethyl-) guanine, Wuhan Pusheng Pharmaceutical Co., Ltd., the accurate word H42020129 of product batch number 110811 traditional Chinese medicines).(embodiment 1 method prepares, and lot number is respectively: 20110508,20110509,20110510,20110511) for wall tapestry extract, wall tapestry extract C, wall tapestry extract A, wall tapestry extract B
2, experimental technique
2.1 experiment in vitro.
2.1.1 drug cytotoxicity measures (MTT method)
Cell suspension is inoculated in 96 porocyte culture plates with 8 × 105/ml density, every hole 200 μ l, 37 DEG C, 5%CO
2, 100% relative humidity cultivates 24h.Wall tapestry extract, wall tapestry extract C, wall tapestry extract A, the equal doubling dilution of wall tapestry extract B are to following 6 concentration: 16,8,4,2,1,0.5mg/ml, and add in cell suspension hole, each drug level repeats 4 holes, separately establishes normal cell controls.Continue under the same terms to cultivate 33h, observation of cell pathological changes (CPE) situation, and detect cell survival rate with MTT method.
2.1.2 virus virulence measures (plaque method)
By cell suspension with 8 × 10
5/ ml density is inoculated in 24 porocyte culture plates, every hole 1mL, 37 DEG C, 5% CO
2, 100% relative humidity cultivates 24h.Viral dilution is to following 6 concentration: 10
-3, 10
-4, 10
-5, 10
-6, 10
-7, 10
-8, add in cell suspension hole, each drug level repeats 4 holes, separately establishes normal cell controls, and methylcellulose covering covers, and continues to cultivate 72h, violet staining, counting under the same terms.
Infectious virus amount (PFU/ml)=(speckle number in every hole/every hole virus inoculation amount ml) × viral dilution multiple.
2.1.3 medicine invades the blocking effect (plaque method) of cell to HSV-II
Test sample liquid is mixed with HSV-II equal-volume, infects Vero cell with this virus drugs mixed liquor.37 DEG C, 5%CO
2absorption 90min, washing, adds cell maintenance medium and puts 37 DEG C, 5%CO
2cultivate.Every day observes CPE, detects viral suppression after 72h with plaque method.Therapeutic index (TI) is adopted to weigh the suppression effect of drug on viral as evaluation index.Therapeutic index (TI)=half toxic concentration (TC
50)/half suppresses dense (IC
50).Each drug level repeats 4 holes, arranges normal cell controls, drug control and virus control simultaneously.
2.1.4 to the direct deactivation (plaque method) of HSV-II
Test sample liquid is mixed with HSV-II equal-volume, after 37 DEG C of effect 90min, infects Vero cell with this virus drugs mixed liquor.37 DEG C, 5% CO
2absorption 90min, washing, the same method is cultivated and is checked.
2.1.5 to the inhibitory action (plaque method) of virion propagation
By virus infected cell, wash, add the test sample liquid of variable concentrations after absorption 90min, the same method is cultivated and is checked.Viral suppression (%)=(virus control group on average goes out speckle number-medicine-feeding test group and on average goes out speckle number)/virus control group on average goes out speckle number.
2.2 experiment in vivo.
2.2.1 medicine is to the determination of acute toxicity of mice
Cleaning grade Kunming mouse random packet, often organizes 6, male and female half and half.According to Vitro Experimental Results, select to suppress the active total extract preferably of HSV-II biosynthesis, with 400,500,625,800,1000,1250mg/kg dosage gastric infusion, separately establish negative control group, give isopyknic normal saline.Normal feed water inlet, Continuous Observation 10d, record dead mouse situation also calculates LD50.
2.2.2 viral encephalocoele model toxicity test
Cleaning grade Kunming mouse random packet often organizes 10, male and female half and half.After infection site routine disinfection, through the right side
Intracerebroventricular virus, viral dilution is to following 6 concentration: 10
-1, 10
-2, 10
-3, 10
-4, 10
-6, 10
-7, infective dose is every 0.05mL.Normal feed water inlet, Continuous Observation 10d, record dead mouse situation also calculates LD by Reed-Muench method
50.
2.2.3 medicine infects the protective effect of HSV-II mice to encephalocoele
Cleaning grade Kunming mouse random packet often organizes 10, male and female half and half.After infection site routine disinfection, through right ventricle injecting virus, 24h after viral infection, drug treatment.By medicine LD
501/2 ~ 1/4 as the high test dose of medicine experiment in vivo, LD
501/12 ~ 1/16 as low test dose, height 2 dosage groups established by every medicine.Without the matched group (virus control group, Normal group) of medicine, continuous gastric infusion 5d, observes animal morbidity and death condition, continuous 30d.
3, experimental result
3.1 experiment in vitro.
3.1.1. drug cytotoxicity measures
Table 3 wall tapestry extract is to the toxicity (unit: mg/ml) of Vero cell
The toxic action of test sample liquid to Vero cell shows as that cell proliferation is slow, granule is more, refractivity is poor, morphologic change, part cell breakage come off.Because cell metabolic activity reduces or death, the viable count that MTT method detects reduces.
3.1.2 virus virulence measures (plaque method)
Vero cell is more responsive to HSV-II, and the Vero cell pathological changes effect CPE caused by HSV-II infects is characterized as circle contracting swelling, mutually merges formation thyrsiform or starlike, even part cell detachment, forms focus.It is 10 that plaque counting obtains HSV-II type (3 generation) 20110913 infectious virus amount (PFU/ml)
7.57pFU/ml, this HSV-II virus adopts 10
-5time every hole go out speckle number and be about 40, easily count, therefore adopt 10
-5as the viral dilution of subsequent experimental.
3.1.3 HSV-II is invaded to the blocking effect of cell
Table 4 wall tapestry extract invades the blocking effect of Vero cell to HSV-II.
3.1.4 medicine is to the direct killing effect of HSV-II
The each extract of table 5. wall tapestry is to the direct deactivation of HSV-II.
3.1.5 medicine inhibitory action (plaque method) that HSV-II virion is bred
The inhibitory action that each effective site of table 6. wall tapestry is bred HSV-II virion.
Wall tapestry extract is by multicomponent, and too many levels, multipath ground plays synergism and shows antiviral efficacy, invades to HSV-II the Main Function approach that the blocking effect of cell and direct kill virus are wall tapestry extracorporeal antivirus effects.HSV-II is tunicary virus, and outermost peplos is made up of lipid and glycoprotein, and wherein any one composition changes, and can make peplos degeneration, thus inactivation of viruses.Experimental result shows that each extract of wall tapestry is comparatively strong to the direct deactivation of HSV-II, and especially the effect of wall tapestry extract and wall tapestry extract A direct deactivation HSV-II is more remarkable than ACV.Therefore infer that these chemical compositions can make peplos degeneration with inactivation of viruses.The blocking effect research that HSV-II invades cell shows, wall tapestry extract not only has antiviral activity, also has the effect that to a certain degree Cell protection prevents Virus entry.Utilize HSV-II encephalitis model to study wall tapestry extract to the protective effect of HSV-II infecting mouse, result shows that wall tapestry extract shows certain antiviral activity.
Claims (4)
1. the application of wall tapestry extract in preparation antiviral drugs, the preparation method of described wall tapestry extract is:
(1) wall tapestry, adds 8-15 times of water gaging, soaks 4-12 hour, adopts extraction by steam distillation volatile oil, extraction time 1-4 hour, extraction time 1-3 time, collects volatile oil, obtains wall tapestry extract A; Wall tapestry aqueous extract is filtered, obtains extracting solution A and medicinal residues A respectively;
(2) step (1) being obtained medicinal residues A concentration 50%-95% ethanol is solvent, heating and refluxing extraction, and extraction time is 1-3 time, and each extraction time is 1-3 hour, each solvent load is 8-15 times of wall tapestry weight, filters, and extracting solution reclaims ethanol, concentrated, dry, obtain wall tapestry extract B;
(3) by the extracting solution A that step (1) obtains, be concentrated into relative density 1.10-1.20, pass through macroporous adsorptive resins, first wash with water, then use the alcoholic solution eluting of concentration 50%-70%, collect different concentration ethanol eluent, concentrate drying, obtains wall tapestry extract C;
(4) by above-mentioned wall tapestry extract A, wall tapestry extract B, the mixing of wall tapestry extract C, wall tapestry extract is obtained.
2. application according to claim 1, is characterized in that the preparation method of described wall tapestry extract is:
(1) wall tapestry, adds 12 times of water gagings, soaks 6 hours, adopts extraction by steam distillation volatile oil, 2 hours extraction times, extraction time 2 times, collects volatile oil, obtains wall tapestry extract A; Wall tapestry aqueous extract is filtered, obtains extracting solution A and medicinal residues A respectively;
(2) step (1) being obtained medicinal residues A concentration 70% ethanol is solvent, heating and refluxing extraction, and extraction time is 2 times, and each extraction time is 2 hours, each solvent load is 12 times of wall tapestry weight, filters, and extracting solution reclaims ethanol, concentrated, dry, obtain wall tapestry extract B;
(3) by the extracting solution A that step (1) obtains, be concentrated into relative density 1.12, by DM130 macroporous adsorbent resin, first wash with water, then use the alcoholic solution eluting of concentration 60%, collect 60% concentration ethanol eluent, concentrate drying, obtain wall tapestry extract C;
(4) by above-mentioned wall tapestry extract A, wall tapestry extract B, the mixing of wall tapestry extract C, wall tapestry extract is obtained.
3. application according to claim 1, is characterized in that the antiviral drugs that described wall tapestry extract and chemical drugs or Chinese medicine or natural drug form.
4. application according to claim 1, is characterized in that described wall tapestry extract, by adding the various adjuvants that pharmaceutics allows, makes tablet oral on pharmaceutics, granule, capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310525392.9A CN103585189B (en) | 2013-10-31 | 2013-10-31 | The application of wall tapestry extract in preparation antiviral drugs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310525392.9A CN103585189B (en) | 2013-10-31 | 2013-10-31 | The application of wall tapestry extract in preparation antiviral drugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103585189A CN103585189A (en) | 2014-02-19 |
| CN103585189B true CN103585189B (en) | 2015-10-28 |
Family
ID=50075643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310525392.9A Expired - Fee Related CN103585189B (en) | 2013-10-31 | 2013-10-31 | The application of wall tapestry extract in preparation antiviral drugs |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103585189B (en) |
-
2013
- 2013-10-31 CN CN201310525392.9A patent/CN103585189B/en not_active Expired - Fee Related
Non-Patent Citations (3)
| Title |
|---|
| 地衣化学成分和药理作用研究进展;房敏峰等;《中草药》;20111231;第42卷(第12期);2571-2576 * |
| 地衣抗生素和地衣多糖类物质的研究进展;张璞等;《山东科学》;20070430;第20卷(第2期);41-44 * |
| 河北雾灵山地衣的研究Ⅲ;李学东等;《首都师范大学学报（自然科学版）》;20060228;第27卷(第1期);67-72 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103585189A (en) | 2014-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102961469B (en) | Traditional Chinese medicine dispersible tablet for treating upper respiratory infection, and preparation method and quality detection method thereof | |
| CN102688332B (en) | A kind of Chinese medicine composition for the treatment of flu and preparation method thereof | |
| CN106580979B (en) | Application of the pyridine heterocycle ester type compound in the drug for preparing anti-Coxsackie virus type B3 | |
| CN106668013A (en) | Application of pyridine aromatic ester compounds to preparation of medicaments for resisting enterovirus 71 | |
| CN111676197B (en) | Vibrio harveyi phage, phage composition and application thereof | |
| CN106309455B (en) | The purposes of Peimisine | |
| CN103585225B (en) | The application of a kind of Herba of Artemisiae admsii extract in preparation antiviral drugs | |
| CN103585189B (en) | The application of wall tapestry extract in preparation antiviral drugs | |
| CN105168374B (en) | Application of the thinfruit hypecoum herb extract in preparation antiviral drugs | |
| KR101653884B1 (en) | A Coxsackie virus proliferation inhibitory composition extracted from Isodon excisus | |
| CN103768157A (en) | Veterinary antiviral traditional Chinese medicine Ziqi effervescent granules and preparation method thereof | |
| CN103610705B (en) | The application of Spiraea alpina extract in preparation antiviral drugs | |
| CN101167822B (en) | Tibetan medicine bongga extraction and its application in preparing antiviral medicine | |
| CN106668015B (en) | A kind of fat-based ester type compound WY124 is preparing the application in anti-enterovirus medicines | |
| CN104510754A (en) | Antiviral pharmaceutical composition | |
| JP2023026528A (en) | Cyanobacterial extract, method for preparing the same and uses thereof | |
| CN106668012B (en) | Application of the nitrogen-containing heterocycle aromatic ester compound in the drug for preparing anti-Coxsackie virus type B3 | |
| CN104490915A (en) | Antiviral pharmaceutical composition | |
| CN104510756A (en) | Antiviral pharmaceutical composition | |
| CN104490907A (en) | Antiviral pharmaceutical composition | |
| CN104510748A (en) | Antiviral pharmaceutical composition | |
| CN104873529A (en) | Antiviral drug composition containing nuciferine | |
| CN100364975C (en) | Medication for anti virus of respiratory tract and application | |
| CN104510755A (en) | Antiviral pharmaceutical composition | |
| CN103816199B (en) | A kind of anti-duck virus hepatitis Chinese medical extract compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: MENG JIANJUN Free format text: FORMER OWNER: JINAN XINGYI MEDICAL TECHNOLOGY CO., LTD. Effective date: 20150908 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Meng Jianjun Inventor after: Meng Jianguo Inventor before: Kong Qianqian |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: KONG QIANQIAN TO: MENG JIANJUN MENG JIANGUO |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20150908 Address after: 307 Anqiu people's Hospital, No. 5, building 2, 259 health Road, Anqiu, Shandong, Weifang 262199, China Applicant after: Meng Jianjun Address before: 250101 No. 51 Industrial South Road, Ji'nan hi tech Zone, Shandong, Ji'nan Applicant before: Jinan Xingyi Medical Technology Co.,Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151028 Termination date: 20161031 |